ERA

Download the full-sized PDF of Lipopolymer Mediated siRNA Therapy for Cancer: Focus on Acute Myeloid LeukemiaDownload the full-sized PDF

Analytics

Share

Permanent link (DOI): https://doi.org/10.7939/R3WW77750

Download

Export to: EndNote  |  Zotero  |  Mendeley

Communities

This file is in the following communities:

Graduate Studies and Research, Faculty of

Collections

This file is in the following collections:

Theses and Dissertations

Lipopolymer Mediated siRNA Therapy for Cancer: Focus on Acute Myeloid Leukemia Open Access

Descriptions

Other title
Subject/Keyword
RNAi
Acute myeloid leukemia
SDF-1
Suspension cells
AML patient cells
THP-1
HL60
Breast cancer cells
siRNA
Adherent cells
Bone marrow stromal cells
Polyethylenimine
Non-viral carrier
KG-1
PEI
CXCR4
Cancer
Lipid
CXCL12
Proliferation
Lipopolymer
Type of item
Thesis
Degree grantor
University of Alberta
Author or creator
Landry, Breanne K
Supervisor and department
Uludag, Hasan (Chemical and Materials Engineering)
Examining committee member and department
Uludag, Hasan (Chemical and Materials Engineering)
Heidenreich, Olaf (Molecular Haematology)
Hitt, Mary (Oncology)
Lai, Raymond (Laboratory Medicine & Pathology)
Kaur, Kamaljit (Pharmacy and Pharmaceutical Sciences)
Department
Department of Chemical and Materials Engineering
Specialization
Materials Engineering
Date accepted
2015-03-25T13:34:56Z
Graduation date
2015-06
Degree
Doctor of Philosophy
Degree level
Doctoral
Abstract
Protein silencing by small interfering RNA (siRNA) is a promising treatment strategy for cancer as over-expression of proteins is largely responsible for cancer cells’ infinite proliferation, evasion of cell death and multi-drug resistance. However, siRNAs require a carrier as their biological instability, negative charge and large molecular weight prevent cellular delivery. In this thesis, I first provide a review of current non-viral siRNA carrier strategies designed to protect and deliver the siRNA to the cell cytoplasm for RNAi activity and then follow with an over-view of the current state of siRNA development with non-viral carriers specifically in leukemia. One promising cationic polymer for siRNA delivery is high molecular weight polyethylenimine (PEI); however, its toxicity is an obstacle for clinical use. This thesis investigates a library of low-molecular weight (2 kDa) PEI with hydrophobic (lipid) modifications as siRNA carriers. The lipid modification renders this otherwise ineffective low-toxic polymer a safe and effective delivery system for intracellular siRNA delivery and protein silencing. We first explore a lipid modified polymer library in adherent cells lines targeting a model protein target, the house-keeping gene, glyceraldehyde 3-phosphate dehydrogenase (GAPDH), and several relevant cancer targets; P-glycoprotein (P-gp), breast cancer resistance protein (BCRP) and survivin. These initial studies in adherent cells demonstrated that although the exact formulations for efficient silencing depended on the cell line and protein target, silencing with two of the lipid-modified polymers (caprylic and linoleic acid substitutions) were consistently effective, suggesting that these carriers can be applied clinically. Fine-tuning of the siRNA/polymer composition was however critical for silencing particular targets. We then focus our efforts specifically on Acute Myeloid Leukemia (AML), where siRNA therapy development has lagged behind the cancers that are derived from attachment dependent cells, as evident in the included review of current efforts in AML siRNA therapy. We explored the feasibility of the lipid-modified carriers in AML cell lines. Efficient siRNA delivery and silencing of the model protein target, green fluorescent protein (GFP), was achieved with higher functionality than that of 25 kDa PEI, where again caprylic acid and linoleic acid substitutions stood out as the most desirable polymer substitutions. Further work demonstrated effective silencing of an AML therapeutic target CXCR4, a surface expressed adhesion protein that contributes to leukemic cell survival. The suppression of CXCR4 as well as its ligand, SDF-1 (CXCL12), resulted in a decrease in overall cell survival, which was largely attributed to a decrease in cell proliferation without enhanced effects when silencing the two targets simultaneously. The decrease in cell numbers due to CXCR4/SDF-1 silencing occurred both in the absence and presence of human bone marrow stromal cells (hBMSC), suggesting that the proposed approach would be effective in the presence of the protective bone marrow microenvironment. In more clinically related models, siRNA delivery was achieved in all human AML patient cells tested and CXCR4 silencing was demonstrated in some cases, ex vivo. The effects of silencing CXCR4 in an AML subcutaneous in vivo tumor model were also explored. Overall, we found that caprylic and linoleic lipid-substituted PEI2 can provide effective siRNA delivery to leukemic cells and can be employed in molecular therapy of leukemia targeting suitable proteins, such as CXCR4, with therapeutic outcomes. We conclude with a discussion on the further development of siRNA carriers with focus on AML therapy, describing potential enhancements that could move the field forward.
Language
English
DOI
doi:10.7939/R3WW77750
Rights
Permission is hereby granted to the University of Alberta Libraries to reproduce single copies of this thesis and to lend or sell such copies for private, scholarly or scientific research purposes only. Where the thesis is converted to, or otherwise made available in digital form, the University of Alberta will advise potential users of the thesis of these terms. The author reserves all other publication and other rights in association with the copyright in the thesis and, except as herein before provided, neither the thesis nor any substantial portion thereof may be printed or otherwise reproduced in any material form whatsoever without the author's prior written permission.
Citation for previous publication
Aliabadi, Hamidreza M. Landry, Breanne. Sun, Chongbo, Tang, Tian. Uludağ, Hasan. (2011). Supramolecular Assemblies in Functional siRNA Delivery: Where Do We Stand? Biomaterials.  http://www.sciencedirect.com/science/article/pii/S0142961211014335Aliabadi
, Hamidreza M. Landry, Breanne. Bahadur, Remant K. Neamnark, Artphop. Suwantong, Orawan. Uludağ, Hasan. (2011). Impact of Lipid Substitution on Assembly and Delivery of siRNA by Cationic Polymers. Macromolecular Bioscience.  http://onlinelibrary.wiley.com/doi/10.1002/mabi.201000402/abstractAliabadi
, Hamidreza M. Landry, Breanne. Mahdipoor, Parvin. Uludağ, Hasan. (2011). Induction of Apoptosis by Survivin Silencing through siRNA Delivery in a Human Breast Cancer Cell Line. Molecular Pharmaceutics.  http://pubs.acs.org/doi/abs/10.1021/mp200176vAliabadi
, Hamidreza M. Landry, Breanne. Mahdipoor, Parvin. Hsu, Charlie YM. Uludağ, Hasan. (2012). Effective Down-Regulation of Breast Cancer Resistance Protein (BCRP) by siRNA Delivery Using Lipid-Substituted Aliphatic Polymers. European Journal of Pharmaceutics and Biopharmaceutics.  http://www.sciencedirect.com/science/article/pii/S0939641112000124Landry
, Breanne. Aliabadi, Hamidreza M. Samuel, Anuja. Gül-Uludağ, Hilal. Xiaoyan, Jiang. Kutsch, Olaf. Uludağ, Hasan. (2012). Effective Non-Viral Delivery of siRNA to Acute Myeloid Leukemia Cells with Lipid-Substituted Polyethylenimines. PLoS ONE.  http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0044197Valencia-Serna
, Juliana. Landry, Breanne. Xiaoyan, Jiang. Uludağ, Hasan. (2014). Potential of siRNA Therapy in Chronic Myeloid Leukemia. Springer.  http://link.springer.com/chapter/10.1007/978-94-017-8896-0_21

File Details

Date Uploaded
Date Modified
2015-06-15T07:08:29.536+00:00
Audit Status
Audits have not yet been run on this file.
Characterization
File format: pdf (PDF/A)
Mime type: application/pdf
File size: 12881126
Last modified: 2015:10:21 23:52:56-06:00
Filename: Landry_Breanne_K_201503_PhD.pdf
Original checksum: 2cf669ee289b8ffb7e4592c3f8f58c4e
Activity of users you follow
User Activity Date